Introduction ▼
Antipsychotic polypharmacy (APP), defi ned as the concurrent use of 2 or more antipsychotic drugs, is not uncommon in clinical practice [ 1 ] , particularly for treatment-resistant schizophrenia patients [ 2 ] . For example, Medicaid data show that the rate of American schizophrenia patients on APP increased from 3.3 % in 1999 to 13.7 % in 2004 [ 3 ] . Previous studies also found that APP was more common in Asian patients compared with their Western counterparts [ 4 , 5 ] . At the same time, however, to date there has no convincing evidence of improved effi cacy for APP.
Research support for APP is largely restricted to open-label trials [ 6 ] rather than double-blind, controlled investigations [ 3 , 7 ] . Further more, some studies found that APP increased adverse eff ects and the cost of treatment [ 3 , 8 ] . In order to reduce the inappropriate use and maximize the benefi ts of APP, it is vital to understand how it is being used in clinical practice. In 1999 a large-scale longitudinal, observational, Multiple logistic regression analysis of the whole sample revealed that patients on APP were younger, had a higher dose of antipsychotics in chlorpromazine equivalents, and more severe positive and negative symptoms. They were also more likely to receive depot and fi rst-generation antipsychotic drugs.
Conclusions:
The frequency of APP prescription varied between countries and territories, suggesting that a host of clinical and socio-cultural factors played a role in determining APP use in Asia. To resolve the discrepancy between treatment recommendation and clinical practice, regular reviews of prescription patterns are needed.
prescription trends from 2001 to 2009 and (ii) to explore the demographic and clinical correlates of APP with increased power compared with earlier reports [ 9 ] .
Patients and Methods ▼ Settings, study design, and subjects 
Statistical analysis
The data were analyzed using SPSS 13.0 for Windows. Comparisons among the 3 cohorts with respect to the proportion of individuals prescribed APP in each study site were conducted using χ-square tests. Comparisons between antipsychotic monotherapy (APM) and APP with respect to socio-demographic and clinical characteristics were performed by independent samples t-test, Mann-Whitney U test, and χ-square test, as appropriate. Multiple logistic regression analysis was used to determine the demographic and clinical variables infl uencing APP. The 1-sample Kolmogorov-Smirnov test was used to check the normality of distribution for continuous variables. The level of signifi cance was set at 0.05 (2-tailed).
Results ▼ • ▶ Table 2 shows the prescribing pattern and the number of antipsychotic drugs prescribed in the 3 surveys. The combinations of second-generation antipsychotics (SGAs) and SGAs, fi rst-generation antipsychotics (FGAs) and SGAs increased, while the combination of FGAs and FGAs decreased over time.
• ▶ Table 3 presents the frequently prescribed antipsychotic drugs. Of them, risperidone and clozapine were the most commonly prescribed SGAs, while haloperidol and chlorpromazine were the most commonly prescribed FGAs.
• ▶ Table 4 compares the socio-demographic and clinical characteristics of patients on APM and APP in the whole sample.
Patients on APP were older, more often to be men and had higher doses of antipsychotics and more severe positive and negative symptoms. They were also more likely to receive depot antipsychotics, mood stabilizers, anticholinergics and FGAs, while less likely to receive antidepressants.
• ▶ Table 5 displays the independent factors that were independently associated with APP. Patients on APP were younger, had a higher dose of antipsychotics in chlorpromazine equivalents, and more severe positive and negative symptoms. They were also more likely to receive depot and FGAs.
Discussion ▼
The major fi nding of this study is that APP was still widely prescribed to more than one third of the schizophrenia patients in this region. In addition, APP decreased in Asia from 46. The frequency of APP in the current sample is broadly in the range of previous fi ndings (12−90 %) in Asian patients [ 9 , 15 ] . For example, APP was found in 17.6 % of 398 randomly selected Chinese schizophrenia outpatients with a signifi cant diff erence between Beijing (7.1 %) and Hong Kong (28 %) [ 16 ] . APP fi gures reported in the present survey are considerably higher than what have been reported for Western patients [ 17 , 18 ] , supporting observations that APP is prescribed more commonly for Asian psychiatric patients [ 4 , 5 , 19 ] . In recent years a number of clinical pharmacological studies have concluded that there was no substantial proof of improved effi cacy for APP, while at the same time this practice could increase adverse eff ects and the cost of treatment [ 3 , 6 , 8 ] . Downloaded by: Chinese University of Hong Kong. Copyrighted material.
APP [ 24 ] . APP was more often prescribed for patients with more severe negative and positive psychotic symptoms in this study probably because of the need to optimize the dopamine-2 receptor occupancy and to target a variety of receptors beyond the dopamine-2 receptor [ 9 , 26 ] , although this justifi cation for APP lacks robust research data [ 27 , 28 ] . APP was also related to more prescriptions of depot antipsychotics. Because of the lack of fl exibility of depot drugs, the practice of temporarily augmenting depot antipsychotics with oral drugs could be justifi ed. First-generation antipsychotics (FGAs) are cheap and readily available across Asia, which could explain why they were more often used in patients on APP.
There are a number of limitations to this study. First, as the survey comprised only inpatients, the results cannot be applied to all schizophrenia patients in Asia. Second, some important environmental factors likely to infl uence appropriate prescription of APP, such as local prescription guidelines, the type of psychiatric facilities and reimbursement policies were not evaluated. In addition, there are diff erences in health-care schemes, prescribing traditions and treatment guidelines between countries, and even institutions even within one country, such as China and India. The potential confounding eff ects of these diff erences need be explored in the future. Third, psychopathology and drug side eff ects were not evaluated with standardized rating instruments nor was inter-rater reliability assessed prior to the study. Fourth, the conversion of antipsychotic doses into CPZeq is not completely accurate, particularly for SGAs and depot agents [ 29 ] . Fifth, the 3 surveys took place in diff erent centers in some study sites, which may have distorted the longitudinal comparison across centers. The limitations of this study are partly off set by its strengths, including the large sample size and the ethnic diversity of the sample. Overall, the comparison of the 3 surveys may approximate trends in the prescription patterns for schizophrenia inpatients in Asia.
In conclusion, the fi ndings of the 3 surveys indicate that the prescription patterns of APP for Asian schizophrenia inpatients have fl uctuated considerably over the past decade. It is unclear whether this trend was the result of better educational eff orts, the distribution of the fi ndings of the fi rst 2 REAP studies in the region and the introduction of more SGAs in clinical practice, or a combination of these and other, yet unknown, factors.
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